Breast Cancer Research and Treatment

, Volume 161, Issue 2, pp 375–384

Discordance between original and central laboratories in ER and HER2 results in a diverse, population-based sample

  • Jennifer J. Griggs
  • Ann S. Hamilton
  • Kendra L. Schwartz
  • Weiqiang Zhao
  • Paul H. Abrahamse
  • Dafydd G. Thomas
  • Julie M. Jorns
  • Rachel Jewell
  • Maria E. Sibug Saber
  • Reina Haque
  • Steven J. Katz
Epidemiology

DOI: 10.1007/s10549-016-4061-z

Cite this article as:
Griggs, J.J., Hamilton, A.S., Schwartz, K.L. et al. Breast Cancer Res Treat (2017) 161: 375. doi:10.1007/s10549-016-4061-z

Abstract

Purpose

To investigate the discordance between original and central laboratories in estrogen receptor (ER) status, in tumors originally deemed to be ER-negative, and in HER2 status in a diverse population-based sample.

Methods

In a follow-up study of 1785 women with Stage I–III breast cancer diagnosed between 2005 and 2007 in the Detroit and Los Angeles County SEER registry catchment areas, participants were asked to consent to reassessment of ER (in tumors originally deemed to be ER-negative) and HER2 status on archival tumor samples approximately four years after diagnosis. Blocks were centrally prepared and analyzed for ER and HER2 using standardized methods and the guidelines of the American Society of Clinical Oncology and the College of American Pathologists. Analyses determined the discordance between original and central laboratories.

Results

132 (31%) of those eligible for ER reassessment and 367 (21%) eligible for HER2 reassessment had archival blocks reassessed centrally. ER discordance was only 6%. HER2 discordance by immunohistochemistry (IHC) was 26%, but final HER2 results—employing FISH in tumors that were IHC 2+ at the central laboratory—were discordant in only 6%. Half of the original laboratories did not perform their own assays.

Conclusions

Discordance between original and central laboratories in two large metropolitan areas was low in this population-based sample compared to previously reported patient samples. Centralization of testing for key pathology variables appears to be occurring in many hospitals. In addition, quality improvement efforts may have preceded the publication and dissemination of specialty society guidelines.

Keywords

Breast cancer Estrogen receptor HER2 SEER registry Pathology 

Supplementary material

10549_2016_4061_MOESM1_ESM.doc (36 kb)
Supplementary material 1 (DOC 36 kb)

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • Jennifer J. Griggs
    • 1
  • Ann S. Hamilton
    • 2
  • Kendra L. Schwartz
    • 3
  • Weiqiang Zhao
    • 4
  • Paul H. Abrahamse
    • 1
  • Dafydd G. Thomas
    • 1
  • Julie M. Jorns
    • 1
  • Rachel Jewell
    • 4
  • Maria E. Sibug Saber
    • 2
  • Reina Haque
    • 5
  • Steven J. Katz
    • 1
  1. 1.University of MichiganAnn ArborUSA
  2. 2.Keck School of MedicineUniversity of Southern CaliforniaLos AngelesUSA
  3. 3.Wayne State University School of MedicineDetroitUSA
  4. 4.The Ohio State UniversityColumbusUSA
  5. 5.Kaiser Permanente Southern California, Research & EvaluationPasadenaUSA

Personalised recommendations